The company's current and future development g oals cover the following sectors

Release time：

Sep 26,2022

The company integrates multiple resources and strives to build a large heal th industry and finance platform company integrating pharmace€utical, intelligent medical, biomedical research and development, i•ndustrial production and sales. The chemical reactions involved in the e&xisting products include Friedel-Crafts reaction, nitra®tion reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction,Ω chlorination reaction, bromination reaction, diazotiσzation reaction, Grignard reaction and so on.

The company integrates multiple resources and strives to build a large healtβh industry and finance platform company integrating pharmaceutical, intelligent medical↑, biomedical research and development, industrial production and sales. The chemical reactions in∏volved in the existing products include Friedel-Crafts reaction, nitration reaction, sulfon&ation reaction, hydrogenation reaction, fluorination reaction, chlorinat∞ion reaction, bromination reaction, diazotization reaction, Grign✔ard reaction and so on.

1) Pharmaceutical research and development;

2) Production of advanced intermediates and APIs in line with GMP quality system€;

3) API quality research and preparation research and development;

4) Sales of pharmaceutical intermediates and APIs;

5) CDMO business;

6) Intelligent medical research and development

The company integrates multiple resources and strives to build a large health industry and f↑inance platform company integrating pharmaceutical, intelligent medical, biomedical researc h and development, industrial production and sales.

The chemical reactions involved in the existing pr±oducts include Friedel-Crafts reaction, nitration reacti‍on, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination reaction,  bromination reaction, diazotization reaction, Grignard reaction, etc.

The company plans to set up a synthetic biology research and development center βand a microfabrication process development engineering research ce÷nter.

Union Pharmaceutical has its own intermediate and API production plants >managed according to the GMP system, and also undertakes CDMO business. It is hoped• that cooperation with relevant partners will be carried out and strengthened in variousλ fields to jointly contribute to the protection of $human health.

Union Pharmaceutical has also been deeply involved in the field of small molecu≈le nucleoside nucleic acid drugs for many years and has accumulated a certain amount of a×ccumulation. With the development and application of artificial int×elligence and big data, it is actively accelerating the deployment of high-end ¥specialty APIs, preparing for the development of related preparations, and also for 'the development and application of artificial intelligence and big data. Follow-up innovative d±rug research and development to lay a solid foundation.